OBJECTIVE: In this study, we sought to examine the prevalence, correlates, and consequences associated with simultaneous polydrug use and concurrent polydrug use of alcohol and prescription drugs. For purposes of this investigation, simultaneous polydrug use referred to the co-ingestion of different drugs at the same time, and concurrent polydrug use referred to the use of different drugs on separate occasions within the past 12 months. METHOD: Undergraduate students attending a large public midwestern university in the United States were randomly selected to self-administer a Web survey. The sample consisted of 4,580 undergraduate students, with a mean (SD) age of 19.9 (2.0) years; the sample consisted of 50% women, and the racial breakdown was 65% white, 13% Asian, 7% black, 5% Hispanic, and 10% other race/ethnicity. The survey assessed simultaneous polydrug use and concurrent polydrug use of alcohol and four classes of prescription drugs: (1) pain medication, (2) stimulant medication, (3) sedative medication, and (4) sleeping medication. RESULTS: The 12-month prevalence for polydrug use involving alcohol and abusable prescription drugs was 12.1% (including 6.9% simultaneous polydrug use). The majority of polydrug use involving alcohol and each class of prescription drugs was simultaneous polydrug use, with the exception of sleeping medication. Simultaneous polydrug use was more prevalent among undergraduate students who were male, were white, and reported early initiation of alcohol use. Simultaneous polydrug use was associated with more alcohol-related and other drug use-related problems than concurrent polydrug use. CONCLUSIONS: Based on the high prevalence and increased risk for consequences associated with simultaneous polydrug use of alcohol and prescription drugs, collegiate prevention efforts aimed at reducing substance abuse should clearly focus on co-ingestion of alcohol and prescription drugs.
OBJECTIVE: In this study, we sought to examine the prevalence, correlates, and consequences associated with simultaneous polydrug use and concurrent polydrug use of alcohol and prescription drugs. For purposes of this investigation, simultaneous polydrug use referred to the co-ingestion of different drugs at the same time, and concurrent polydrug use referred to the use of different drugs on separate occasions within the past 12 months. METHOD: Undergraduate students attending a large public midwestern university in the United States were randomly selected to self-administer a Web survey. The sample consisted of 4,580 undergraduate students, with a mean (SD) age of 19.9 (2.0) years; the sample consisted of 50% women, and the racial breakdown was 65% white, 13% Asian, 7% black, 5% Hispanic, and 10% other race/ethnicity. The survey assessed simultaneous polydrug use and concurrent polydrug use of alcohol and four classes of prescription drugs: (1) pain medication, (2) stimulant medication, (3) sedative medication, and (4) sleeping medication. RESULTS: The 12-month prevalence for polydrug use involving alcohol and abusable prescription drugs was 12.1% (including 6.9% simultaneous polydrug use). The majority of polydrug use involving alcohol and each class of prescription drugs was simultaneous polydrug use, with the exception of sleeping medication. Simultaneous polydrug use was more prevalent among undergraduate students who were male, were white, and reported early initiation of alcohol use. Simultaneous polydrug use was associated with more alcohol-related and other drug use-related problems than concurrent polydrug use. CONCLUSIONS: Based on the high prevalence and increased risk for consequences associated with simultaneous polydrug use of alcohol and prescription drugs, collegiate prevention efforts aimed at reducing substance abuse should clearly focus on co-ingestion of alcohol and prescription drugs.
Authors: William A Watson; Toby L Litovitz; Wendy Klein-Schwartz; George C Rodgers; Jessica Youniss; Nicole Reid; Wayne G Rouse; Rebecca S Rembert; Douglas Borys Journal: Am J Emerg Med Date: 2004-09 Impact factor: 2.469
Authors: Edward J Cone; Reginald V Fant; Jeffrey M Rohay; Yale H Caplan; Mayra Ballina; Robert F Reder; Daniel Spyker; J David Haddox Journal: J Anal Toxicol Date: 2003-03 Impact factor: 3.367
Authors: William S John; He Zhu; Paolo Mannelli; Geetha A Subramaniam; Robert P Schwartz; Jennifer McNeely; Li-Tzy Wu Journal: Drug Alcohol Depend Date: 2018-11-26 Impact factor: 4.492
Authors: Amelia E Talley; Kenneth J Sher; Douglas Steinley; Phillip K Wood; Andrew K Littlefield Journal: J Stud Alcohol Drugs Date: 2012-03 Impact factor: 2.582
Authors: Francisco Caamaño-Isorna; Nayara Mota; Alberto Crego; Montserrat Corral; Socorro Rodríguez Holguín; Fernando Cadaveira Journal: Int J Public Health Date: 2010-10-27 Impact factor: 3.380
Authors: Helene R White; Jason R Kilmer; Nicole Fossos-Wong; Kerri Hayes; Alexander W Sokolovsky; Kristina M Jackson Journal: Alcohol Clin Exp Res Date: 2019-05-28 Impact factor: 3.455
Authors: Sean Esteban McCabe; Philip T Veliz; Carol J Boyd; Ty S Schepis; Vita V McCabe; John E Schulenberg Journal: Drug Alcohol Depend Date: 2018-11-15 Impact factor: 4.492